CAT
Caterpillar Inc.
CAT's fundamentals are strong, but it looks expensive: trading at 24x earnings, above its usual 18x. Analysts expect strong earnings growth, though they disagree widely on how much.
CTRM
Castor Maritime Inc.
There isn't enough reported data to score CTRM yet.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTRM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
CTRM's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
CTRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 0.4x | $1.31 | — |
| Cheap | 0.5x | $1.82 | +39% |
| Fair | 1x | $3.44 | +163% |
| Expensive | 1.9x | $6.31 | +382% |
Historical ranges are pointers, not guarantees.
CTRM has the edge over CAT in the historical PE scenario, which offers more potential upside but is not a forecast.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
CTRM Forward outlook
There aren't enough analyst estimates for CTRM to show an outlook.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.73 | +17% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
CTRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.32 | +$6.89 |
| Q4 2025 | $0.36 | -5.3% |
| Q4 2024 | $0.38 | -78% |
| Q4 2023 | $1.70 | -86% |
| Q2 2023 | $9.50 | +9.2% |
| Q4 2022 | $12.50 | +166% |
CTRM has the edge over CAT in the latest year-over-year earnings comparison.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT's operating margin was 20% last quarter, up 3.1 points from the same quarter a year ago.
CTRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $46.8M | +22% |
| Q4 2025 | $43.5M | +47% |
| Q2 2025 | $38.3M | +4.4% |
| Q4 2024 | $29.6M | -70% |
| Q2 2024 | $36.7M | -26% |
| Q4 2023 | $97.5M | -30% |
| Q2 2023 | $49.7M | -59% |
| Q4 2022 | $140M | +36% |
CTRM has the edge over CAT in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 156% | +81 points |
| Q4 2025 | 36% | +14 points |
| Q2 2025 | -90% | -111 points |
| Q4 2024 | -20% | -74 points |
| Q2 2024 | 75% | +33 points |
| Q4 2023 | 23% | -23 points |
| Q2 2023 | 22% | -8 points |
| Q4 2022 | 54% | +65 points |
CTRM has the edge over CAT on profitability, with a higher operating margin.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
CTRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$62.8M | -$58.6M |
| Q4 2025 | $13.6M | +$67.7M |
| Q2 2025 | -$4.2M | -118% |
| Q4 2024 | -$54.1M | -351% |
| Q2 2024 | $23.8M | +186% |
| Q4 2023 | $21.6M | +22% |
| Q2 2023 | $8.3M | -72% |
| Q4 2022 | $17.6M | +$64.4M |
CTRM's free cash flow was −$108M over the past year, against $71M the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over CTRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
CTRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +502% | +48.5M shares |
| 1 year | +514% | +48.7M shares |
| 3 years | +242296% | +58.2M shares |
CTRM has 58M diluted shares, up 514% from a year ago.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
CTRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -0.6x | Net Cash |
| Q2 2023 | 0.8x | Very low |
| Q4 2022 | 0.1x | Very low |
| Q2 2022 | 0.3x | Very low |
| Q4 2021 | 0.9x | Very low |
| Q2 2021 | 0.3x | Very low |
| Q4 2020 | 1.8x | Healthy |
CTRM has more cash than debt.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CTRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 4.8 | Oversold |
CTRM's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.1% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
CTRM PE vs Industrials Sector
| Metric | CTRM | Sector median | Relative |
|---|---|---|---|
| PE | 0.4x | 24x | 98% below |
| PE % | 1 | 59 | 58 pts below |
CTRM has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has stronger trend alignment. CAT is above 2 of 5 weekly averages versus CTRM above 0 of 4.
CTRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.65 | 21% below |
| 20 week MA | $1.98 | 34% below |
| 50 week MA | $2.04 | 36% below |
| 100 week MA | $2.17 | 40% below |
CTRM is in a downtrend: it's below all four of its weekly moving averages, and 40% below its 100-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over CTRM on returns for 2026, with the stronger performance.
CTRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $8.84 | $4.25 | -52% |
| 2024 | $4.25 | $2.88 | -32% |
| 2025 | $2.88 | $2.32 | -19% |
| 2026 YTD | $2.32 | $1.31 | -44% |
CTRM has finished every year since 2023 lower, and it's down 44% so far in 2026.